CAR-T Therapies

Videos

Bijal Shah, MD, Discusses the Future of KTE-X19 CAR-T Therapy for R/R B-ALL

06/24/2021

In part 2 of this video series, Dr Shah, discusses the next steps of the phase 2 ZUMA-3 study of KTE-X19 for R/R B-ALL. These data were presented at the 2021 ASCO Annual Meeting.

In part 2 of this video series,...

06/24/2021

Oncology

Videos

KTE-X19 CAR-T Therapy Demonstrates Clinical Benefit for R/R B-ALL

06/08/2021

In part 1 of this video series, Bijal Shah, MD, shares results from the phase 2 ZUMA-3 study of KTE-X19 for R/R B-ALL. These data were presented at the 2021 ASCO Annual Meeting.

In part 1 of this video series,...

06/08/2021

Oncology

Videos

Prophylactic Tocilizumab Before Anti-CD19 CAR-T Therapy for R/R Lymphoma

12/09/2020

Paolo Caimi, MD, discusses findings from a study examining the use of prophylactic tocilizumab prior to anti-CD19 CAR-T therapy for relapsed/refractory lymphoma.

Paolo Caimi, MD, discusses...

12/09/2020

Oncology

$Anti-BCMA CAR-T Therapy With bb2121 for Relapsed/Refractory MM$

Videos

Anti-BCMA CAR-T Therapy With bb2121 for Relapsed/Refractory MM

09/28/2020

In this video, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.

In this video, Dr Raje discusses...

09/28/2020

Oncology

Videos

CAR T-Cell Therapy: Where Do We Stand in 2019?

11/13/2019

Thomas Kipps, MD, PhD, gives an update on the development of CAR T-cell therapy at the 2019 Lymphoma & Myeloma Congress.

Thomas Kipps, MD, PhD, gives an...

11/13/2019

Oncology

Podcasts

The Use of CAR-T Therapy for B-Cell Lymphomas Outside of Clinical Trials

12/25/2018

Jonathon Cohen, MD, discussed a trial presented at the ASH Annual Meeting on real world results of axicabtagene ciloleucel in B-cell lymphomas.

Jonathon Cohen, MD, discussed a...

12/25/2018

Oncology

Real-World Results Support Axi-Cel Use in B-Cell Lymphomas Outside of Clinical Trials

12/12/2018

Results from a real-world trial show that axicabtagene ciloleucel can be used outside of clinical trial settings, although outcomes may differ.

Results from a real-world trial...

12/12/2018

Oncology

News

Anti-CD19 CAR-T Therapy Safe, Effective in Large B-Cell Lymphoma

12/05/2018

A follow-up analysis of the ZUMA-1 trial reported 51% of patients receiving axicabtagene ciloleucel were still alive 2 years after treatment.

A follow-up analysis of the...

12/05/2018

Oncology

News

CD19-Targeting CAR-T Therapy Yields Long-Term Response in DLBCL

11/26/2018

In heavily pretreated older adults with relapsed or refractory DLBCL, tisagenlecleucel yielded a high frequency of durable responses, according to study data presented at ASH 2018.

In heavily pretreated older...

11/26/2018

Oncology